Cyxone AB (publ) Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Cyxone AB (publ) Stock Forecast and Price Target
If the average price target of kr0.05 set by distinguished experts for Cyxone AB (publ) over the past few weeks is reached this year, there would be a potential downside of approximately -44.44% from the last closing price in May, 2024. This potential increase is based on a high estimate of kr0.05 and a low estimate of kr0.04. If you are looking to invest in the stock, it's important to research and compare different companies.
-44.44% Downside
Cyxone AB (publ) Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Cyxone AB (publ)'s Price has seen an increase, rising from kr0.00 to kr0.00. This represents a growth of 100.00%. Analysts predict that Cyxone AB (publ)'s Fair Value will increase in the upcoming year, reaching kr0.10. This would represent an increase of 100.00%. Over the next seven years, experts predict that Cyxone AB (publ)'s Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SOBI Stock Forecast | Swedish Orphan Biovitrum AB (p... | Outperform |
16
|
kr280.00 | Buy/Sell | kr293.00 | 16.07% |
| VITR Stock Forecast | Vitrolife AB (publ) | Buy |
18
|
kr165.60 | Buy/Sell | kr250.00 | 32.85% |
| BIOA B Stock Forecast | BioArctic AB (publ) | Outperform |
10
|
kr195.00 | Buy/Sell | kr372.40 | 79.49% |
| KARO Stock Forecast | Karo Healthcare AB | - |
12
|
kr60.70 | Buy/Sell | kr40.00 | -100.00% |
| GENO Stock Forecast | Genovis AB (publ.) | Outperform |
16
|
kr28.50 | Buy/Sell | kr75.67 | 77.19% |
Cyxone AB (publ) Revenue Forecast for 2023 - 2025 - 2030
In the last year, Cyxone AB (publ) has seen a decline in its Revenue, from kr6.40M to kr5.15M – a 19.53% decrease. Analysts predict that Cyxone AB (publ)'s Revenue will increase in the upcoming year, reaching kr6.40M. This would represent an increase of 24.27%. Over the next seven years, experts predict that Cyxone AB (publ)'s Revenue will grow at a rate of 19.55%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BINV Stock Forecast | BioInvent International AB (pu... | Outperform |
10
|
kr26.35 | Buy/Sell | kr107.00 | 214.99% |
| VICO Stock Forecast | Vicore Pharma Holding AB (publ... | Buy |
4
|
kr18.88 | Buy/Sell | kr70.75 | 244.28% |
| HNSA Stock Forecast | Hansa Biopharma AB (publ) | Buy |
6
|
kr28.40 | Buy/Sell | kr123.00 | 230.99% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| XSPRAY Stock Forecast | Xspray Pharma AB (publ) | Outperform |
6
|
kr40.95 | Buy/Sell | kr120.00 | 161.29% |
| MERT A Stock Forecast | Mertiva AB (publ) | - |
9
|
kr0.00 | Buy/Sell | kr0.00 | 0.00% |
| IMMNOV Stock Forecast | Immunovia AB (publ) | - |
0
|
kr1.94 | Buy/Sell | kr0.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ATORX Stock Forecast | Alligator Bioscience AB (publ) | Outperform |
0
|
kr0.91 | Buy/Sell | kr1.83 | 152.75% |
| CANTA Stock Forecast | Cantargia AB (publ) | Buy |
5
|
kr3.24 | Buy/Sell | kr13.67 | 301.23% |
| XBRANE Stock Forecast | Xbrane Biopharma AB (publ) | Outperform |
5
|
kr0.21 | Buy/Sell | kr116.00 | 200.00% |
Cyxone AB (publ) EBITDA Forecast for 2023 - 2025 - 2030
Cyxone AB (publ)'s EBITDA has decreased In the last three years, from kr-47.20M to kr-19.26M – a 59.19% drop. In the next year, analysts predict that EBITDA will reach kr-56.00M – an increase of 190.76%. For the next seven years, the forecast is for EBITDA to grow by 141.13%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMMU Stock Forecast | Mendus AB (publ) |
9
|
kr0.46 | Buy/Sell | kr1.70 | 291.30% | |
| ACE Stock Forecast | Ascelia Pharma AB (publ) |
0
|
kr12.34 | Buy/Sell | kr19.50 | -39.22% | |
| KDEV Stock Forecast | Karolinska Development AB (pub... |
8
|
kr1.58 | Buy/Sell | kr4.70 | 156.33% |
Cyxone AB (publ) EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Cyxone AB (publ)'s EBIT has seen a drop from kr-49.00M to kr-21.80M – a 55.51% decrease. In the next year, analysts are expecting an increase in EBIT, predicting it will reach kr-58.00M – an increase of 166.06%. The Cyxone AB (publ) forecast is for EBIT to reach kr-48.76M or grow by 123.67%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ISR Stock Forecast | ISR Immune System Regulation H... | - |
0
|
kr7.43 | Buy/Sell | kr0.00 | -100.00% |
| HAMLET B Stock Forecast | Hamlet BioPharma AB (publ) | - |
0
|
kr2.60 | Buy/Sell | kr0.00 | -100.00% |
| ONCO Stock Forecast | Oncopeptides AB (publ) |
0
|
kr2.92 | Buy/Sell | kr6.90 | 119.18% |
Cyxone AB (publ) EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Cyxone AB (publ)'s EPS has seen an increase, rising from kr-0.96 to kr0.00. This represents a growth of 100.00%. Analysts predict that Cyxone AB (publ)'s EPS will increase in the upcoming year, reaching kr-0.59. This would represent an increase of 100.00%. Over the next seven years, experts predict that Cyxone AB (publ)'s EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GUARD Stock Forecast | Guard Therapeutics Internation... |
8
|
kr30.00 | Buy/Sell | kr0.23 | 116.67% | |
| IVACC Stock Forecast | Intervacc AB (publ) |
10
|
kr4.38 | Buy/Sell | kr27.00 | 82.65% | |
| SYNACT Stock Forecast | SynAct Pharma AB | - |
7
|
kr6.82 | Buy/Sell | kr15.00 | -100.00% |
.jpg)